Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher J Logothetis

Showing results (171-180 of 251) with videos related to

Pageof 26
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
Oncotarget|June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancerTheodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|October 30, 2012
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy eraSean E McGuire, Andrew K Lee, Jasmina Z Cerne, et al.
Developmental Cell|June 7, 2017
Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate CancerSong-Chang Lin, Yu-Chen Lee, Guoyu Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancerAna M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicitiesSumit K Subudhi, Ana Aparicio, Jianjun Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2015
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate CancerAndreas Varkaris, Paul G Corn, Nila U Parikh, et al.
Endocrine-Related Cancer|September 26, 2024
Body composition in recurrent prostate cancer and the role of steroidogenic genotypeNeha Venkatesh, Rebecca S Tidwell, Yao Yu, et al.
Prostate Cancer and Prostatic Diseases|September 13, 2022
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormonesMinas J Sakellakis, Andrew W Hahn, Sumankalai Ramachandran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancerLouis L Pisters, Curtis A Pettaway, Patricia Troncoso, et al.
Pageof 26

Showing results (171-180 of 251) with videos related to

Sort By:
Pageof 26
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
Oncotarget|June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancerTheodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
International Journal of Radiation Oncology, Biology, Physics|October 30, 2012
PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy eraSean E McGuire, Andrew K Lee, Jasmina Z Cerne, et al.
Developmental Cell|June 7, 2017
Endothelial-to-Osteoblast Conversion Generates Osteoblastic Metastasis of Prostate CancerSong-Chang Lin, Yu-Chen Lee, Guoyu Yu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancerAna M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 5, 2016
Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicitiesSumit K Subudhi, Ana Aparicio, Jianjun Gao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2015
Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate CancerAndreas Varkaris, Paul G Corn, Nila U Parikh, et al.
Endocrine-Related Cancer|September 26, 2024
Body composition in recurrent prostate cancer and the role of steroidogenic genotypeNeha Venkatesh, Rebecca S Tidwell, Yao Yu, et al.
Prostate Cancer and Prostatic Diseases|September 13, 2022
Characterization of prostate cancer adrenal metastases: dependence upon androgen receptor signaling and steroid hormonesMinas J Sakellakis, Andrew W Hahn, Sumankalai Ramachandran, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 23, 2004
Evidence that transfer of functional p53 protein results in increased apoptosis in prostate cancerLouis L Pisters, Curtis A Pettaway, Patricia Troncoso, et al.
Pageof 26